Phase I Dose-escalation Trial of ARRY-380 in Combination With Trastuzumab in Participants With Brain Metastases From HER2+ Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2014 by Dana-Farber Cancer Institute
Sponsor:
Collaborators:
Array BioPharma
Breast Cancer Research Foundation
Information provided by (Responsible Party):
Nancy Lin, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01921335
First received: August 2, 2013
Last updated: March 27, 2014
Last verified: March 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: November 2019
  Estimated Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)